- Price
- $7.75
- Day
- +0.78%
- Mkt Cap
- $626.98M
- 52W Range
- $7.59 – $18.31
- Volume
- 1.50M
- Beta
- 0.51
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low – Time to Sell?
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report)'s stock price hit a new 52-week low during trading on Thursday. The stock traded as low as $7.66 and last traded at $7.69, with a volume of 2071393 shares traded. The stock had previously closed at $8.16. Analyst Ratings Changes Several equities analysts have recently weighed
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $PHAT--PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz LLP[/url] (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September: